PepGen Inc. (PEPG)
NASDAQ:PEPG
Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$1.70
-$0.11(-3.01%)
At close: 4:00 PM EST
$1.70
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$1.01 - $7.80
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$103.75M
Enterprise Value$78.16M
Total Cash (Recent Filing)$132.30M
Total Debt (Recent Filing)$16.56M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding69,169,210
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-45.55
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$10.17Price Target Upside498.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enhanced Delivery (EDO) PlatformPepGen’s EDO platform addresses a fundamental delivery barrier for oligonucleotide therapies by substantially improving cellular and nuclear uptake. This is a durable competitive advantage that can enable higher tissue exposure, broadenable indications, and make the company a more attractive partner or acquirer over the medium term.
Clinical Progress And Global EnrollmentOngoing global enrollment and staged higher-dose readouts provide structural program de-risking: multinational data reduces regulatory concentration risk, and emerging safety/efficacy signals across cohorts support a credible clinical development path that materially affects long-term approval chances.
Cash Runway And Conservative LeverageA reported cash runway into H2 2027 combined with low debt-to-equity reduces near-term refinancing pressure, giving management time to hit key clinical milestones or secure partnerships. This financial cushion supports strategy execution and limits immediate dilution risk compared with highly levered peers.
Bears Say
No Revenue And Persistent LossesPepGen remains a precommercial biotech with no product revenue and sustained multi-year losses. Structural dependence on external funding until commercialization raises execution risk and means shareholder value is contingent on clinical success and later commercial execution, not current cash generation.
FDA Partial Clinical HoldA partial FDA hold driven by preclinical questions materially raises regulatory and timeline risk. Resolving nonclinical concerns can require additional studies, extend development timelines and costs, and impair partner negotiations; this regulatory overhang is a durable constraint until fully cleared.
High Cash Burn And Financing RiskSustained negative operating and free cash flow at scale implies recurring financing needs. Continued high burn pressures capital allocation, risks dilution through equity raises, and forces prioritization of programs—structural constraints that persist until revenue or material partnership income appears.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.01 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $103.75M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 67 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on May 12, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.033.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.29.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,169,210 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 5.952%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.17 (498.04% Upside)
$10.17 (498.04% Upside)
Hedge Fund Trend
Decreased
By 865.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-59.89%
Trailing 12-Months
Asset Growth
22.69%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$10.17
▲(498.04% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
37.05% Insiders
3.69% Mutual Funds
4.24% Other Institutional Investors
51.24% Public Companies and
Individual Investors